FedEx unfazed as USPS and Amazon drop some peak surcharges
Online merchants have one more factor to consider in their choice of parcel carrier for ...
Well-documented fears from incumbents that Amazon has set its sights on the pharmaceutical market have been waylaid – for now at least. The news follows its admission to regulators that it will not use its pharmacy licences to sell prescriptions, but to sell medical devices and supplies instead. The etailer had gained licences from Tennessee and Indiana – but analyst Jeffries, through a freedom of information request, discovered that its application stated it would “not store or ship drugs”. Neverthless, it may perhaps have opted for “lower-hanging fruit” first, before it moves into the drug market. However, an analyst at Pembroke Consulting believes that the pharma market could be a tough one to crack, even for Amazon.
Knights of Old parent enters administration, but sister firm Nelson is saved
EXCLUSIVE: UPS rumoured to have eyes on DB Schenker
Flexport fires CFO and HR VP, but sees need for a head of restructuring
'Peak season already over' as ocean freight rates collapse further
150,000 empty containers stranded in Russia as trade imbalance grows
Manufacturing boom in India drives up intra-Asia freight rates
Rush for e-commerce capacity could trigger airfreight rate rise
Alex Lennane
email: [email protected]
mobile: +44 7879 334 389
During August 2023, please contact
Alex Whiteman
email: [email protected]
Alessandro Pasetti
email: [email protected]
mobile: +44 7402 255 512
Comment on this article